Guardian Pharmacy Services: Confident in the long-term opportunities in LTC: BofA Conference Takeaways

Research evidence excerpt

Guardian Pharmacy Services: Confident in the long-term opportunities in LTC: BofA Conference Takeaways

Accessible version

Guardian Pharmacy Services

Confident in the long-term opportunities in

LTC: BofA Conference Takeaways

Maintain Rating: BUY | PO: 42.00 USD | Price: 34.91 USD

Differentiated LTC player in size, scale, and technology 13 May 2026

We hosted a fireside chat at our Healthcare Conference in Las Vegas, Nevada earlier this Equity

morning with Guardian Pharmacy’s CEO Fred Burke to discuss the company’s

Allen Lutz, CFA

differentiation, competitive landscape, M&A strategy, and long-term growth framework. Research Analyst

The company is seeing strong momentum in the business that allowed them to raise the BofAS +1 646 855 4380

annual guidance after one quarter. Guardian indicated its size and scale is one of the allen.lutz@bofa.com

major reasons the company is differentiated relative to peers, which allows the company Hanna Lee

to purchase drugs better (buy side) as well as capture more favorable reimbursement Research Analyst BofAS

terms. The company is also able to manage patient onboarding well and has industry +1 646 855 3682

leading processes and controls to manage the business effectively. hanna.y.lee@bofa.com

Dev Weerasuriya

Comfortable in driving growth over the long term ResearchBofAS Analyst

Guardian has guided to long-term growth of high-single digit organic growth +1dev.weerasuriya@bofa.com646 855 5707

supplemented by M&A, contemplating low double digit EBITDA growth (excluding the

one-time revenue headwinds from the IRA). CEO Fred Burke also provided more details

on the M&A pipeline and the typical financial profile of prospects. Typically, most

Stock Dataacquisition targets are operating at breakeven or low single digit margins and Guardian